FDA Receives IND for GTB-3650 in CD33+ AML and MDS - Targeted Oncology

Retrieved on: 2023-12-04 15:25:59

Tags for this article:

Click the tags to see associated articles and topics

FDA Receives IND for GTB-3650 in CD33+ AML and MDS - Targeted Oncology. View article details on hiswai:

Excerpt

Compared with GTB-3550, GT Biopharma's lead second-generation Tri-Specific Killer Engager (TriKE) program, GTB-3650 has shown high potency in ...

Article found on: www.targetedonc.com